9JQY image
Deposition Date 2024-09-28
Release Date 2025-10-22
Last Version Date 2025-12-17
Entry Detail
PDB ID:
9JQY
Title:
Structural Insights into Selective Antagonism of TG6-129 and EP4 Prostaglandin Receptor
Biological Source:
Source Organism:
Mus musculus (Taxon ID: 10090)
synthetic construct (Taxon ID: 32630)
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.92 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:GFP-like fluorescent chromoprotein,Prostaglandin E2 receptor EP4 subtype
Gene (Uniprot):PTGER4
Chain IDs:C (auth: A)
Chain Length:549
Number of Molecules:1
Biological Source:synthetic construct, Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Heavy chain of Fab fragment
Chain IDs:A (auth: H)
Chain Length:253
Number of Molecules:1
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Molecule:Light chain of Fab fragment
Chain IDs:B (auth: L)
Chain Length:255
Number of Molecules:1
Biological Source:Mus musculus
Ligand Molecules
Primary Citation
Structural insights into selective and dual antagonism of EP2 and EP4 prostaglandin receptors.
Embo J. 44 7242 7262 (2025)
PMID: 41162752 DOI: 10.1038/s44318-025-00611-0

Abstact

Prostaglandin E2 (PGE2) signaling through EP2 and EP4 receptors is crucial in regulating inflammation, pain, and cancer progression. While selective and dual antagonists for these receptors hold therapeutic potential, their binding mechanisms and selectivity have remained unclear. In this study, we present cryo-electron microscopy (cryo-EM) structures of human EP2 and EP4 receptors in complex with selective antagonists PF-04418948 and grapiprant, as well as with the dual antagonist TG6-129. These structures reveal distinct binding pockets and interaction networks that dictate antagonist selectivity and efficacy. Notably, TG6-129 displays a novel binding mode, engaging deeply with EP2 while interacting more superficially with EP4 in a two-warhead manner. Furthermore, comparisons of active and inactive receptor structures elucidate the mechanisms underlying EP2 activation and antagonism. Overall, these findings provide a structural framework for understanding prostanoid receptor pharmacology and offer valuable insights for the rational design of improved selective and dual antagonists targeting EP2 and EP4 receptors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback